Monovisc is a single-injection, cross-linked hyaluronic acid viscosupplement used to relieve knee osteoarthritis pain. Manufactured by Anika Therapeutics, it is one of the highest-concentration single-injection HA products on the market and has become a popular choice among orthopaedic and sports medicine practitioners looking to simplify their viscosupplementation protocols. This guide covers everything practitioners need to know about Monovisc — from mechanism of action to injection technique, side effects, expected outcomes, and how it compares to other viscosupplements.

What Is Monovisc?

Monovisc is a sterile, viscoelastic, non-pyrogenic solution of cross-linked sodium hyaluronate derived from bacterial fermentation (non-animal sourced). It contains 88 mg of hyaluronic acid in a 4 ml prefilled syringe, at a concentration of 22 mg/ml.

It is the sister product to Orthovisc (a 3- to 4-injection regimen), designed to deliver equivalent therapeutic benefit in a single visit. The cross-linking of the hyaluronic acid chains extends its residence time within the joint, providing prolonged lubrication and cushioning for the cartilage surfaces.

Monovisc is FDA-cleared for use in the United States and CE-marked for Europe. It is indicated for symptomatic relief of knee OA pain in patients who have not adequately responded to non-pharmacological therapy and analgesics.

Bioresus supplies Monovisc and the complete viscosupplementation injectable range at wholesale prices to licensed practitioners.

How Does Monovisc Work?

In a healthy joint, synovial fluid acts as both a lubricant and a shock absorber, protecting articular cartilage during movement. In osteoarthritis, the concentration and molecular weight of naturally occurring hyaluronic acid in synovial fluid decreases, leading to reduced viscosity and elasticity — and consequently, more joint friction, pain, and damage.

Monovisc works by restoring the viscoelastic properties of synovial fluid. The injected hyaluronic acid:

  • Supplements and replaces degraded natural HA in the joint space
  • Reduces friction between articular cartilage surfaces
  • Absorbs mechanical shock during weight-bearing activities
  • May have anti-inflammatory effects by binding to surface receptors on synoviocytes
  • May stimulate endogenous HA production within the joint

The cross-linking of Monovisc’s HA chains means it resists enzymatic degradation more effectively than linear (non-cross-linked) HA, prolonging its residence time in the joint and extending the therapeutic effect.

Indications for Monovisc Injection

Monovisc is indicated for:

  • Symptomatic knee osteoarthritis (Kellgren-Lawrence Grade I–III)
  • Adults who have not responded adequately to conservative management (physiotherapy, weight management, analgesics)
  • Patients seeking a non-surgical pain management option
  • Patients who wish to delay or avoid knee replacement surgery
  • Active patients (athletes, manual workers) requiring pain control without systemic medication

Contraindications

  • Known hypersensitivity to hyaluronic acid or any component of the formulation
  • Active infection in or around the knee joint
  • Skin disease or infection at the proposed injection site
  • Venous or lymphatic stasis in the leg
  • Pregnancy or lactation (limited safety data)

Use with caution in patients receiving anticoagulants (elevated haematoma risk) and those with a history of severe allergic reactions.

Monovisc Dosage and Treatment Protocol

Standard Dosing

The standard Monovisc dosing protocol is:

  • One intra-articular injection of 4 ml (88 mg sodium hyaluronate) into the affected knee
  • Single injection, single visit — no repeat injections in the same course
  • Re-treatment may be considered after 6 months, based on clinical assessment

This single-injection protocol is one of Monovisc’s primary clinical advantages. It eliminates the need for multiple clinic visits, improves patient compliance, and reduces the administrative and scheduling burden on practices.

Frequency of Treatment

Most patients receive one injection every 6 months, though some may respond for longer periods. Clinical reassessment should guide re-treatment timing. Document baseline and follow-up pain scores (VAS/NRS) and functional status (WOMAC/KOOS) to make evidence-based re-treatment decisions.

Monovisc Injection Technique

Equipment Required

  • Monovisc 4 ml prefilled syringe
  • 21–23 gauge needle (not supplied)
  • Sterile gloves
  • Antiseptic skin preparation (e.g., chlorhexidine or povidone-iodine)
  • Sterile draping
  • Optional: local anaesthetic (lidocaine 1% for patient comfort)

Injection Approaches

Monovisc can be administered via several intra-articular approaches:

Superolateral approach (most common for full extension):

  • Patient supine, knee fully extended
  • Insert needle superior and lateral to the patella, directing medially and slightly inferiorly
  • Confirm intra-articular placement; aspirate any significant effusion before injecting
  • Inject 4 ml slowly and evenly

Anteromedial or anterolateral approach (knee flexed at 90°):

  • Patient seated with knee bent at 90°
  • Insert needle adjacent to the patellar tendon, medially or laterally
  • Suitable for patients with difficulty achieving full extension

Ultrasound guidance is strongly recommended for all viscosupplementation injections. Multiple studies demonstrate that ultrasound-guided intra-articular knee injections achieve significantly higher accuracy rates compared to landmark-guided injections, and are associated with improved clinical outcomes, particularly in obese patients.

If significant joint effusion is present, aspirate excess synovial fluid before injecting Monovisc to maximise the therapeutic effect.

Post-Injection Care

  • Advise patients to avoid strenuous physical activity and prolonged weight-bearing for 48 hours post-injection
  • Ice application to the knee may reduce immediate post-injection discomfort
  • Mild swelling, warmth, or stiffness for 24–72 hours post-injection is expected and usually self-limiting
  • Onset of pain relief may take 4–8 weeks; patients should not assess efficacy before this time
  • Schedule a follow-up appointment at 8–12 weeks to assess response

Monovisc Side Effects

Monovisc has a well-documented safety profile. The majority of adverse events are local, mild, and transient.

Common Side Effects

  • Injection site pain — the most frequently reported adverse event, typically short-lived
  • Swelling or joint effusion — usually resolves within 72 hours
  • Warmth or redness around the knee
  • Temporary increased joint stiffness

Less Common Side Effects

  • Acute inflammatory (pseudoseptic) reaction — characterised by sudden onset of joint pain, swelling, and warmth within 24–72 hours post-injection; resolves spontaneously in most cases
  • Headache
  • Back pain

Serious Adverse Events (Rare)

  • Septic arthritis — risk is minimised with strict aseptic technique; patients presenting with fever, rapidly worsening joint pain and systemic signs post-injection should be evaluated urgently
  • Hypersensitivity or allergic reactions — rare with non-animal sourced HA, but practitioners should be equipped to manage anaphylaxis

Advise patients to seek immediate medical attention if they experience increasing rather than improving pain after 72 hours, fever, significant joint swelling with erythema, or any signs of systemic reaction.

Expected Clinical Outcomes

Monovisc’s clinical efficacy has been demonstrated in pivotal randomised controlled trials:

  • Non-inferior to Orthovisc (3-injection regimen) in reducing WOMAC pain scores at 26 weeks
  • Significant reductions in pain VAS scores compared to saline control at 12 and 26 weeks
  • Clinically meaningful improvement in KOOS (Knee Injury and Osteoarthritis Outcome Score) subscales including pain, symptoms, and activities of daily living
  • Pain relief sustained for up to 6 months in the majority of responders
  • Responder rate of approximately 60–75% in mild-to-moderate OA

As with all viscosupplementation products, outcomes are best in patients with mild-to-moderate OA. Patients with severe (Grade IV) bone-on-bone OA are unlikely to achieve meaningful benefit and should be counselled accordingly.

Monovisc vs Other Viscosupplements

When deciding between viscosupplementation products, practitioners should consider injection schedule, HA source, concentration, and cost:

  • Monovisc vs Durolane: Both are single-injection, non-animal sourced HA products. Monovisc has a higher HA concentration (88 mg/4 ml vs 60 mg/3 ml). Both have comparable efficacy profiles.
  • Monovisc vs Orthovisc: Orthovisc requires 3–4 injections; Monovisc achieves similar outcomes in one visit. Orthovisc uses a higher molecular weight HA.
  • Monovisc vs Synvisc-One: Both are single-injection products. Synvisc-One uses avian-derived hylan GF-20; Monovisc uses bacterial fermentation-derived HA with a lower allergy risk profile.
  • Monovisc vs Euflexxa: Euflexxa requires 3 injections; both are non-animal sourced. Monovisc’s single-injection convenience is a clear advantage for patient compliance.

Patient Selection and Counselling

Optimal patient selection is key to achieving good outcomes with Monovisc:

Best candidates:

  • Kellgren-Lawrence Grade II–III knee OA
  • BMI under 35 (higher BMI associated with lower response rates)
  • Non-response to conservative management after adequate trial
  • Patients motivated to manage OA without surgery
  • Active patients or those with occupational demands requiring pain control

Counselling points:

  • Monovisc provides symptomatic relief, not disease modification — it does not reverse cartilage damage
  • Pain relief typically takes 4–8 weeks to onset; patients should not judge efficacy before this period
  • Duration of effect is typically 6 months; re-injection can be considered at that point
  • Some patients do not respond — this is a known limitation of viscosupplementation and should be discussed pre-treatment

Ordering Monovisc Wholesale

Licensed practitioners can order Monovisc at wholesale prices from Bioresus. Bioresus is a UK-based wholesale supplier to licensed aesthetic and medical practitioners, offering competitive pricing, reliable stock availability, and fast dispatch.

All Bioresus products are sourced from authorised distributors and supplied with full documentation to support practice compliance requirements.

Conclusion

Monovisc represents a clinically proven, convenient option for knee osteoarthritis viscosupplementation. Its single-injection protocol, high HA concentration, non-animal origin, and strong safety and efficacy data make it a practical choice for practitioners offering a viscosupplementation service. Proper patient selection, accurate injection technique — ideally ultrasound-guided — and clear patient counselling on realistic timelines and outcomes are the keys to achieving consistently good results.

With the growing demand for non-surgical joint management and the increasing focus on delaying knee replacement in suitable patients, viscosupplementation with products like Monovisc is an important service for orthopaedic, sports medicine, and aesthetic practitioners to offer.